This post reviews the issue of bone disease in prostate cancer
This post reviews the issue of bone disease in prostate cancer as well as the evolving role from the novel agent denosumab, a completely human monoclonal antibody that inhibits the receptor activator of nuclear factor-B ligand, in suppressing bone resorption and offering bone protection within this disease. trial, demonstrating a hold off in skeletal-related occasions … [Read more…]